Johnson & Johnson is starting to look less like a defensive healthcare giant and more like a growth story. The harder question is how much investors should pay before that growth fully arrives.
The company raised its 2026 outlook after second-quarter sales increased 6.6% to $25.3 billion. Adjusted EPS rose 4.7% to $2.90, while full-year adjusted EPS guidance increased to $11.60-$11.75. Management now expects reported sales of $100.8 billion-$101.4 billion, putting Johnson & Johnson on track to cross $100 billion in annual revenue for the first time. More importantly for valuation, consensus expects earnings growth to accelerate considerably after 2026. Whether JNJ’s premium is justified becomes more interesting when you see where it ranks among the 10 best healthcare stocks to buy according to hedge funds.
The Multiple Is Pricing In Faster Earnings
Consensus estimates put Johnson & Johnson at 23.11 times 2026 earnings and 21.16 times 2027 earnings before the multiple falls more sharply to 17.30 times in 2028 and 14.19 times in 2029. That decline depends on EPS growth accelerating from 2.66% in 2026 to 9.25% in 2027, 22.29% in 2028, and 21.94% in 2029.
Those expectations are notable against an industry where median forward diluted EPS growth is 10.26%. JNJ’s own forward growth rate is currently 6.64%, below the industry median, meaning today’s valuation increasingly depends on the later acceleration actually materializing.
JPMorgan captured that tension on September 29, raising its target to $285 from $270 while remaining Neutral. The firm called Johnson & Johnson one of the cleaner names in the group with sustained top-tier growth, but said the favorable setup was becoming better reflected in the valuation. UBS takes the other side of that debate with a Buy rating and $320 target, supported by above-consensus revenue and EPS estimates through 2030-2032 and what it sees as substantial pharmaceutical pipeline upside.
The Pipeline Has to Deliver the Acceleration
Recent clinical progress helps explain why estimates become more ambitious later in the decade.
ICOTYDE produced sustained plaque-psoriasis skin clearance through Week 112 in data released October 2, strengthening the clinical case behind a potentially important future franchise. The commercial expectations were already moving higher before those results: on September 29, BofA raised its peak psoriasis sales estimate for ICOTYDE to $4.5 billion from $2.4 billion, increasing its expected market share to 18% from 10%.
As reported on September 25, 2026, TREMFYA also met its primary and major secondary endpoints in the Phase 4 STAR study, while five-year CARVYKTI data released the same day strengthened JNJ’s multiple-myeloma franchise.
The growth case extends beyond pharmaceuticals. Earlier, FDA authorization of OTTAVA in July gave MedTech an entry into soft-tissue surgical robotics, while the $1 billion Firefly Bio acquisition added a novel oncology platform. That diversification matters because management is not relying on one blockbuster to produce the expected earnings acceleration. JNJ already has 28 platforms generating more than $1 billion in annual revenue.
The balance sheet gives it room to keep investing. Johnson & Johnson ended Q2 with approximately $21 billion in cash and marketable securities against $49 billion of debt. Year-to-date free cash flow reached roughly $8.7 billion, and management expects the full-year figure to approach $21 billion.
AbbVie Shows What JNJ’s Premium Has to Earn
The comparison with AbbVie Inc. (NYSE:ABBV) makes the valuation hurdle clearer. AbbVie trades at an estimated 18.76 times 2026 earnings and 16.16 times 2027 earnings, compared with 23.11 and 21.16 times for Johnson & Johnson. Yet AbbVie consensus EPS growth is already expected at 40.07% in 2026 and 16.07% in 2027.
That growth has a more immediate commercial foundation. In the second quarter, Skyrizi revenue reached $5.51 billion and Rinvoq generated $2.53 billion, helping AbbVie’s immunology portfolio grow 15.1%, while neuroscience revenue increased 20.3%. AbbVie Inc. is also spending to extend that runway, completing its roughly $10.9 billion Apogee Therapeutics acquisition in September and adding zumilokibart to a pipeline increasingly tasked with generating growth beyond its existing franchises.
JNJ’s case is different. Investors are paying more today partly for earnings acceleration expected farther out, including 22.29% growth in 2028. That makes the comparison more than a question of which company carries the lower P/E. AbbVie Inc.’s multiple is being supported by powerful nearer-term earnings expansion and established growth franchises, while more of JNJ’s premium depends on its newer pharmaceutical assets and MedTech investments turning into substantially faster earnings growth later in the decade.
We recently examined AbbVie’s valuation more closely against Eli Lilly and Company (NYSE:LLY), where the difference in their expected earnings growth reveals two very different ways investors are pricing pharmaceutical growth.
Institutional positioning has strengthened alongside that expectation. Second-quarter hedge fund ownership of JNJ increased to 117 funds from 113. Fisher Asset Management increased its position 44% to 13.3 million shares and Marshall Wace added 26%, although AQR reduced its position 18%. AbbVie Inc. also attracted 88 hedge funds, up from 87 in the previous quarter, while the value of their holdings increased to $8.56 billion from $4.25 billion.
JNJ’s Premium Depends on the Earnings Acceleration Actually Arriving
That leaves a clear valuation test. Johnson & Johnson does not merely need its pipeline and MedTech investments to produce growth. It needs them to deliver the earnings acceleration that makes today’s premium considerably less demanding by 2028 and 2029.
READ NEXT: Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk? and Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?
Hedge Fund Resource Center